NCT01089595View on ClinicalTrials.gov

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

March 31, 2012

Conditions
GISTMetastatic Disease
Interventions
DRUG

Nilotinib

Nilotinib 400 mg po bid

DRUG

Nilotinib with Imatinib

Nilotinib 400 mg po BID Imatinib 400 mg po daily

Trial Locations (3)

19111

Fox Chase Cancer Center, Philadelphia

63110

Siteman Cancer Center, Washington University School of Mediciine, St Louis

27157-1082

Wake Forest University, Winston-Salem

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Fox Chase Cancer Center

OTHER

NCT01089595 - Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | Biotech Hunter | Biotech Hunter